No label defined (Q30894)
Jump to navigation
Jump to search
No description defined
- Danazol's use for menstrual suppression in transgender individuals: A retrospective multi-site cohort study.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
No description defined |
|
Statements
Danazol is a synthetic progestin with androgenic effects that is approved by the Food and Drug Administration for treatment of endometriosis, benign fibrocystic breast disease, and hereditary angioedema. (English)
In recent years, increasing numbers of transgender and nonbinary individuals seeking menstrual suppression have been offered danazol due to its potential to both induce amenorrhea and cause reversible androgenic side effects including pigmentation of vellus hairs and voice changes, which may be desirable in this population. (English)
There are currently no studies assessing use of danazol within the transgender population for menstrual suppression. (English)
This study's primary aim was to evaluate the use of danazol as a menstrual suppression agent in transgender patients. (English)
This was a retrospective multisite cohort study of all individuals who had been on danazol at two tertiary care centers between 2000 and 2022. (English)
All patients prescribed danazol were identified using a search of the electronic medical records. (English)
For demographic purposes, comparisons were made between those who did and did not use danazol for the purpose of menstrual suppression. (English)
A detailed chart review was then performed to analyze the experiences of menstrual suppression in transgender and nonbinary patients. (English)
Most transgender and nonbinary patients on danazol for menstrual suppression remained on it at their most recent follow-up visit, and many charts noted improvements in gender dysphoria, pelvic pain, dysmenorrhea, endometriosis, and heavy menstrual bleeding. (English)
Most transgender patients achieved amenorrhea. (English)
Danazol may be a reasonable option for menstrual suppression in transgender and nonbinary patients. (English)
Our findings show its potential to not only induce amenorrhea but cause desired androgenic symptoms and improve gender dysphoria, pelvic pain, dysmenorrhea, endometriosis, and heavy bleeding. (English)
While the androgenic effects of danazol are less desirable in cisgender populations, it is an attractive option for menstrual suppression in transgender and nonbinary patients. (English)
<b>Using danazol to stop periods in transgender individuals</b>Danazol has previously been used to help treat pain and bleeding related to endometriosis. (English)
However, danazol can have certain androgenic side effects (acne, deepening of the voice) that cisgender women (individuals who were assigned female at birth and identify with the female gender) often find undesirable, but that could be desirable in transgender patients seeking to affirm their gender by stopping periods. (English)
Our study looked at danazol use for period suppression, as well as for other reasons. (English)
We found that most transgender patients using danazol for period suppression found it to be successful and remained on it at follow-up appointments, and that many transgender patients saw improved gender dysphoria, pelvic pain, pain during periods, endometriosis, and heavy period bleeding. (English)
These findings suggest that danazol may be a good option for menstrual suppression in transgender individuals as any experienced androgenic effects may help with gender dysphoria, whether individuals are not yet ready to start testosterone or do not desire testosterone therapy at all. (English)
Ava (English)
Scatoni (English)
A
Steven (English)
Staffa (English)
S
Rosemary Claire (English)
Roden (English)
RC
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Roden is a Nexplanon trainer for Organon, Inc. (English)
No other authors have any conflicts of interest or disclosures. (English)